Suction device and dressing

Information

  • Patent Grant
  • 11766512
  • Patent Number
    11,766,512
  • Date Filed
    Tuesday, May 24, 2022
    2 years ago
  • Date Issued
    Tuesday, September 26, 2023
    a year ago
Abstract
Some embodiments are directed to a system 10 for the application of topical negative pressure therapy to a site 18 on the body of a mammal. Some embodiments of the system 10 comprise a piston 22 and cylinder 24 device 12 having a self-contained power source for the generation of a reduced pressure and for aspirating the site 18. Some embodiments of the system 10 comprise a dressing 14 sealably surrounding the site 18 that can be operably connected to the device 12 by a conduit means 16 to apply the reduced pressure to the site 18.
Description
BACKGROUND
Field of the Invention

Some embodiments of the present application relate to treating a site on a body by applying reduced or negative pressure to the site.


Description of the Related Art

The treatment of open or chronic wounds that are too large to spontaneously close or otherwise fail to heal has long been a troublesome area of medical practice. Closure of an open wound requires inward migration of surrounding epithelial and subcutaneous tissue. Some wounds, however, are sufficiently large or infected that they are unable to heal spontaneously. In such instances, a zone of stasis in which localized edema restricts the flow of blood to the epithelial and subcutaneous tissue forms near the surface of the wound. Without sufficient blood flow, the wound is unable to successfully fight bacterial infection and is accordingly unable to close spontaneously.


An initial stage of wound healing is characterized by the formation of granulation tissue which is a matrix of collagen, fibronectin, and hyaluronic acid carrying macrophages, fibroblasts, and neovasculature that forms the basis for subsequent epithelialization of the wound. Infection and poor vascularization hinder the formation of granulation tissue within wounded tissue, thereby inhibiting wound healing. It therefore becomes desirable to provide a technique for increasing blood circulation within wounded tissue to promote spontaneous healing and to reduce infection.


Another problem encountered during the treatment of wounds is the selection of an appropriate technique for wound closure during the healing process. Sutures are often used to apply force to adjacent viable tissue in order to induce the edges of a wound to migrate together and heal. However, sutures apply a closure force to only a very small percentage of the area surrounding a wound. When there is scarring, edema, or insufficient tissue, the tension produced by the sutures can become great causing excessive pressure to be exerted by the sutures upon the tissue adjacent to each suture. As a result, the adjacent tissue often becomes ischemic thereby rendering suturing of large wounds counterproductive. If the quantity or size of the sutures is increased to reduce the tension required of any single suture, the quantity of foreign material within the wound is concomitantly increased and the wound is more apt to become infected. Additionally, the size or type of a particular wound may prevent the use of sutures to promote wound closure. It therefore becomes desirable to provide an apparatus and method for closing a large wound that distributes a closure force evenly about the periphery of the wound.


Wounds resulting from ischemia, or lack of blood flow, are also often difficult to heal since decreased blood flow to a wound may inhibit normal immune reaction to fight infection. Patients that are bedridden or otherwise non-ambulatory are susceptible to such ischemic wounds as decubitus ulcers or pressure sores. Decubitus ulcers form as a result of constant compression of the skin surface and underlying tissue thus restricting circulation. Since the patient is often unable to feel the wound or to move sufficiently to relieve the pressure, such wounds can become self-perpetuating. Although it is common to treat such wounds with flaps, the conditions that initially caused the wound may also work against successful flap attachment. Wheelchair-bound paraplegics, for example, must still remain seated after treatment of pelvic pressure sores. It therefore becomes desirable to provide a treatment procedure for ischemic wounds that can be conducted in situ upon an immobile or partially mobile patient.


Other types of wounds in which ischemia leads to progressive deterioration include partial thickness burns. A partial thickness burn is a burn in which the cell death due to thermal trauma does not extend below the deepest epidermal structures such as hair follicles, sweat glands, or sebaceous glands. The progression of partial thickness burns to deeper burns is a major problem in burn therapy. The ability to control or diminish the depth of burns greatly enhances the prognosis for burn patients and decreases morbidity resulting from burns. Partial thickness burns are formed of a zone of coagulation, which encompasses tissue killed by thermal injury, and a zone of stasis. The zone of stasis is a layer of tissue immediately beneath the zone of coagulation. Cells within the zone of stasis are viable, but the blood flow is static because of collapse of vascular structures due to localized edema. Unless blood flow is re-established within the zone of stasis soon after injury, the tissue within the zone of stasis also dies. The death of tissue within the zone of stasis is caused by lack of oxygen and nutrients, reperfusion injury (re-establishment of blood flow after prolonged ischemia), and decreased migration of white blood cells to the zone resulting in bacterial proliferation. Again, it becomes desirable to provide a technique for treating burn wounds by enhancing blood circulation to the wounded tissue to inhibit burn penetration.


There exist apparatuses utilizing reduced pressure for treatment of these types of wounds. However, the existing apparatuses do not have adequate means to provide access to the area of the wound beneath the cover or dressing without disturbing the seal (be it adhesive or otherwise) between the dressing and the healthy skin surrounding the wound. Additionally, use of the existing apparatuses is often limited to locally available power sources, or such apparatuses otherwise experience limitations in terms of the amount of suction that can be provided to the dressing in the absence of electrical power.


SUMMARY OF SOME EMBODIMENTS

Some embodiments set forth herein are directed to systems, methods and apparatuses for wound therapy. In particular, some embodiments disclosed herein relate to a system for the generation and application of reduced pressure (compared with ambient atmospheric pressure) to a site on a human or animal body and to a dressing (also referred to herein as a cover) at a wound site, and some embodiments relate to a wound dressing system configured to allow a user or medical practitioner to easily access a wound bed without disturbing a seal between the dressing and the healthy skin surrounding the wound. However, it will be appreciated that the systems, methods and apparatuses disclosed herein may have application to other fields. In certain preferred embodiments, the wounds being treated may include, but are not limited to, acute and chronic wounds, orthopedic trauma wounds, and post-Cesarean wounds, to name a few.


Some embodiments disclosed herein are directed to treating such wounds by a method for the application of topical negative pressure therapy to a site on the body of a mammal, the method comprising: providing a device comprising a cylinder, a piston disposed in the cylinder, and a power source operably connected to the piston, the power source being configured to exert a constant force on the piston; operably connecting the device to a dressing at the site by an aspirant conduit means, wherein the dressing can sealably surround the site; and applying a reduced pressure to the site. In some embodiments, the power source can be a self-contained mechanical motive power source such as, but not limited to, a resilient tension applying device. For example, without limitation the mechanical motive power source can be a coiled ribbon spring. The reduced pressure applied to the site can be held constant by the constant force exerted by the power source on the piston of the device. In some embodiments, the cylinder and piston can comprise a syringe type device, and the reduced pressure can be generated by actuating the piston of the device. Any of the configurations of the method for the application of topical negative pressure therapy to a site on the body of a mammal described above can further comprise operably connecting a mechanical pump (which can be a hand operated pump) to the dressing to generate the reduced pressure.


Some embodiments disclosed herein are directed to treating such wounds with a system for the application of topical negative pressure therapy to a site on the body of a mammal, the system comprising: a piston and cylinder device having a self-contained power source for the generation of a reduced pressure and for aspirating the site; and a dressing at the site operably connected to the device by an aspirant conduit or other conduit means to apply the reduced pressure to the site; wherein the dressing can sealably surround the site. In some embodiments, the device for the generation of reduced pressure can be a self-contained mechanical motive power source such as, but not limited to, a resilient tension applying device or other device that can apply a constant tension force. Some arrangements of the motive power source can have a coiled ribbon spring.


In any of the previously described embodiments, exudate from the site can be received by the piston and cylinder device, and/or the system can further be provided with a separate receptacle for receiving waste. Further, the piston and cylinder device can be a syringe-type device, and the device for the generation of reduced pressure can be a hand-held pump. Further, in any of the previously described embodiments, the dressing can comprise a first adherent base portion configured to sealably surround the site and a second detachable portion sealably and removably connectable to the first base portion. The first base portion and the second detachable portion of the dressing can have mutually engageable connection features which can, but are not required to, comprise male and female engaging portions and/or magnetic pieces such as magnetic tape or magnetic strips. Further, the second detachable portion can include an integral occlusive drape portion or membrane, and at least one of the first base portion, the second detachable portion, and the occlusive drape portion can be provided with a tubular spigot for the attachment of at least one separate aspirant conduit portion.


In some embodiments, any of the embodiments of the dressing described above can have a separate occlusive drape portion. Further, in any of the embodiments disclosed herein, either the first base portion or the second detachable portion, or both portions, can have an aspirant conduit incorporated therein. In some embodiments, the aspirant conduit can be incorporated with a separate occlusive drape portion. In any of the embodiments disclosed herein, the dressing or site can be provided with a wound filler and/or an absorbent material to absorb at least a portion of exudate from the site. The absorbent material can comprise, without limitation, polyacrylate particles. In some embodiments, the absorbent material can comprise carbomethoxycellulose.


Some embodiments disclosed herein are directed to a method of treating a wound comprising: sealably surrounding a wound site with a dressing having an adherent first base portion, and sealably connecting a second detachable portion to the first base portion. In some embodiments, the method can further comprise positioning an occlusive drape between the first and second base portions, while some embodiments of the second detachable portion can substantially completely cover the first base portion. Any of the embodiments of the methods of treating a wound described above can further comprise applying reduced pressure to the wound site.


In some embodiments, such wounds can be treated using an apparatus for the application of topical negative pressure therapy to a site on the skin of the body of a mammal, the apparatus comprising: a dressing configured to sealingly surround the site, the dressing comprising: a base portion configured to be supported by the skin surrounding the site, the base portion optionally comprising an aperture formed axially therethrough; a detachable portion removably supportable by the base portion; and a flexible membrane removably supportable by the base portion, the flexible membrane optionally being configured to at least cover the aperture formed in the base portion; wherein each of the base portion, the detachable portion, and the membrane are optionally formed from a substantially impermeably material; and the dressing can be configured to form an approximately hermetically sealed enclosure over the site when the detachable portion and the flexible membrane are supported by the base portion.


In some embodiments, the apparatus can further comprise a reduced pressure generation device (which can be, without limitation, a piston and cylinder device such as a syringe) configured to provide reduced pressure to the dressing, wherein the apparatus can be configured such that the reduced pressure generation device is in fluid communication with the dressing. Additionally, the reduced pressure generation device can comprise a self-contained mechanical motive power source which can be, without limitation, a rolled spring. In some embodiments, the reduced pressure generation device can comprise a hand-held pump.


In some embodiments, such wounds can be treated using an apparatus for providing a source of reduced pressure to a cover, the apparatus comprising a conduit in communication with the cover; a first suction device configured to allow a user to reduce the pressure within the conduit, the first suction device being removably connectable to a valve member in communication with the conduit; a second suction device configured to allow a user to maintain the reduced pressure within the conduit, the second suction device being removably connectable to the valve member; and a power source configured to provide power to the second suction device.


In some embodiments, such wounds can be treated using a method for the application of topical negative pressure therapy to a site on the body of a mammal, the method comprising: operating a first source of negative or reduced pressure so as to provide reduced pressure to the cover; and disconnecting the first source of negative or reduced pressure from the cover without the loss of a substantial amount of reduced pressure in the cover.


In some embodiments, such wounds can be treated using a method for the application of topical negative pressure therapy to a site on the body of a mammal, the method comprising: sealingly enclosing the site with a cover so that ambient air is substantially prevented from entering a space between the cover and the site; connecting a suction device to the cover through a conduit so that the suction device is in fluid communication with the cover; operating the suction device until a desired level of reduced pressure within the dressing is achieved; connecting a mechanical vacuum system to the conduit so that the mechanical vacuum system is in fluid communication with the cover; providing a power source configured to provide power to the mechanical vacuum system; and operating the mechanical vacuum system so as to maintain a desired level of reduced pressure within the cover.


Some embodiments of the present disclosure are directed to a conduit insertion device for passing a length of conduit through a dressing (which can be, without limitation, any of the dressings disclosed herein), the conduit insertion device having a trocar supported within a length of conduit or tubing. In some embodiments, the conduit insertion device can be used to pass the conduit through either the flexible sheet or the second detachable portion of any of the embodiments of the dressing disclosed herein after the dressing has been positioned over the wound. Some arrangements of the conduit insertion device can be configured such that, after the conduit has been passed through the flexible sheet or the second detachable portion (if the flexible sheet is not use), a tabbed or flanged surface that can be formed on a portion of the conduit can be sealably adhered or otherwise attached to the outside surface of the flexible sheet or second detachable portion to secure the conduit thereto.


For example, in some embodiments, a trocar can be supported within the tubular length of conduit that can be inserted through the dressing such that the trocar protrudes past the distal end of the conduit. In this configuration, the trocar can be used to create a puncture hole in the flexible sheet, the second detachable portion of the dressing, and/or the base portion of the dressing to permit the tubing to pass therethrough. After the tubing has been passed therethrough, the conduit member may be advanced to a distance that is sufficient to permit an annular tabbed or flanged surface sealingly surrounding the tubing to be attached to, adhered to, or otherwise joined with the outside surface of the dressing so that an approximately hermetic seal is formed between the conduit member and the dressing, at which point the trocar may be withdrawn.





BRIEF DESCRIPTION OF THE DRAWINGS

These and other features, aspects and advantages will now be described in connection with certain embodiments, with reference to the accompanying drawings. The illustrated embodiments, however, are merely examples and are not intended to be limiting. The following are brief descriptions of the drawings.



FIG. 1A is a schematic representation of the side of an embodiment of a topical negative pressure therapy system.



FIG. 1B is a schematic representation of the end of an embodiment of a spring unit that can be used with the embodiments of the topical negative pressure therapy system illustrated in FIG. 1A.



FIG. 2 is a schematic representation of the side of another embodiment of a topical negative pressure therapy system.



FIG. 3A is an exploded sectional view through the center of an embodiment of a dressing that can be used in a topical negative pressure therapy system.



FIG. 3B is a sectional view through the center of the embodiment of the dressing shown in FIG. 3A showing a portion of the embodiment of the dressing in an assembled state.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The following detailed description is now directed to certain specific embodiments of the disclosure. In this description, reference is made to the drawings wherein like parts are designated with like numerals throughout the description and the drawings. It is to be noted that any of the features, components, configurations, sizes, materials, or any other details set forth in this disclosure with regard to particular embodiments are meant to also be combinable or substitutable with the components, features, or other details of any other embodiment disclosed herein where such a combination or substitution of such components, features, or other details is suitable.


Preferred embodiments described herein relate to wound therapy. The term “wound” as used herein, in addition to having its broad ordinary meaning, includes any body part of a patient that can be treated using reduced pressure. Wounds include, but are not limited to, open wounds, pressure sores, ulcers and burns. Treatment of such wounds can be performed using negative pressure wound therapy, wherein a reduced or negative pressure can be applied to the wound to facilitate and promote healing of the wound. Additional descriptions of devices, methods, and systems that can be used for wound therapy (e.g., for aspiration, irrigation, and cleansing of wounds) can be found in international patent application publication numbers WO 2004/037334 (titled “APPARATUS FOR ASPIRATING, IRRIGATING AND CLEANSING WOUNDS”), WO 2005/046760 (titled “WOUND CLEANSING APPARATUS WITH HEAT”), and WO 2005/105180 (titled “APPARATUS FOR ASPIRATING, IRRIGATING AND/OR CLEANSING WOUNDS”), the entirety of each of which is hereby incorporated by reference as if fully set forth herein. It will also be appreciated that the negative pressure systems and methods as described herein can be applied to other parts of the body, and are not necessarily limited to treatment of wounds.


The apparatus and methods disclosed herein involve covering of the wound site with a dressing which can be configured to be sealed to the skin surrounding the wound by a flexible membrane type material through which or sealed thereto are conduits or tubes that can carry fluids to the wound site and/or away from the wound site. The fluids can be liquids such as wound exudates and/or irrigation or cleansing fluids such as saline, for example, but can also be gases such as air, for example, used to aerate the wound site and to assist the liquid fluids away from the wound site by aspiration means.


The above-referenced patent application publications WO 2004/037334, WO 2005/046760, and WO 2005/105180 describe systems for treating wounds by therapy usually involving a plurality of conduits needing to be sealed in respect of the dressing/wound site in order to prevent ingress of ambient atmosphere into the wound site and to enable the apparatus to work effectively and efficiently without significant leakage. Other embodiments of apparatuses are disclosed herein which apply topical negative pressure therapy to a wound having only one conduit or tube passing into the wound site.


As mentioned, there is a need for simple and inexpensive topical negative pressure therapy systems in, for example, third world countries and also for use by patients who wish to be mobile to continue daytime occupations while continuing beneficial topical negative pressure therapy. In some embodiments, a device can be provided that mitigates some of the disadvantages of known systems of reduced pressure generation.


Thus, according to some embodiments of the present disclosure, there is provided a system for the application of topical negative pressure therapy to a site on the body of a mammal (which can be a wound or otherwise), the system comprising a piston and cylinder device having a self-contained power source for the generation of a reduced pressure and for aspirating the site. In some embodiments, a dressing can be provided therewith, the dressing configured to cover the site and configured to be connectable to the piston and cylinder device by an aspirant conduit means, such as but not limited to an aspirant conduit or tube. In this arrangement, reduced pressure can be supplied to the dressing and, hence, the site. The dressing can be configured to sealingly surround the site.


In some embodiments, the device for generating a reduced pressure can be a syringe-type device having a cylinder and a slidable piston therein. The device can be configured to operate without a source of A/C power. In some embodiments, so as to be usable by a patient outside of conventional medical facilities such as a hospital or a convalescent bed, for example, the device can have its own power source. The power source can be a conventional battery, for example, powering a conventional DC electric motor driven pump. But, even these configurations can be heavier than desired, and the need to replace or recharge the batteries can be a disadvantage in terms of financial and infrastructural resources. Again, such systems can be relatively costly and also relatively inconvenient in terms of portability and continued power supply.


In some embodiments of the topical negative pressure generating device, the power source can be a mechanically generated motive source driving a simple suction generating unit such as a syringe-type unit, for example. Syringes are commonly available virtually everywhere in the world and are cheap and disposable. Syringes generally comprise a cylinder and an axially slidable piston and are available in a wide range of different sizes. The motive power for moving the piston in the cylinder in one embodiment according to the present disclosure can be a self-contained resilient member such as spring unit, for example. Suitable spring units include, but are not limited to, coiled ribbon springs which are available in many sizes to apply a wide range of forces. Such spring units can effectively apply a constant tension to the piston/piston rod of a syringe. Such a power source can be configured to be lightweight, inexpensive, compact, and portable. The simplicity of the device means it can be operated easily by any patient or clinician with a minimum of training.


Some embodiments of the device can also be provided with suitable features related to pressure measuring means, such as, but not limited to, mechanical or electronic sensors configured to display or reveal the pressure within the dressing and/or syringe cylinder, Some other examples of suitable pressure measuring devices which can be employed include, without limitation, purely pneumatic gauges or electronic gauges such as digital units, perhaps having their own battery power supply.


Some embodiments of the device can also be provided with suitable valve arrangements to ensure that fluid flows are in the correct directions (i.e., so as to prevent air or fluid flow into the dressing) when generating a reduced pressure, and suitable valve arrangements to ensure that reduced pressures are maintained in the dressing. In some embodiments, the valve can be configured such that one or more suction devices (such as, without limitation, a hand pump, suction bulb, a motorized pump, a battery powered pump, a piston and syringe device, or any other suitable suction devices) can be connected and/or disconnected from the valve without the loss of pressure in the dressing.


Although wound exudates can be received directly into the pressure reducing syringe device and expelled therefrom when full into a suitable receptacle or waste disposal system in the case of relatively small wounds, a wound exudate fluid waste collecting receptacle to receive the aspirated exudate fluid from a wound site can be provided as part of the apparatus system in the case of larger wounds, for example. Suitable support means to support and accommodate the various features of the system devices can also be provided.


Additionally, in some embodiments, the system can comprise a manually operated suction device for evacuation of a wound/incision to apply topical negative pressure to the wound and can be used with any dressing design known in the art of topical negative pressure. The device can differ from other spring activated (kinetic devices) in that it can be configured to provide a substantially constant level of pressure throughout the travel range of the piston in the cylinder. This is in contrast to known systems where a significant fall-off in pressure can be measured along the length of travel of a piston or bellows system or in the case of pre-evacuated accumulator bottles or manual pump/reservoir systems where the pressure constantly diminishes as the system or reservoir fills with fluid. Where a syringe-type pressure reducing device is used, the reduced pressure delivered can be controlled by choosing a different size of the syringe. For example, without limitation, the reduced pressure delivered can be controlled by varying the diameter of the syringe cylinder that is appropriate to the type of wound and wound volume. Additionally, without limitation, the reduced pressure delivered can be controlled by varying the size of and/or number of springs used to provide the force on the syringe.


In the system according to certain embodiments, the pressure or rate of pressure change generated can simply be controlled by using an appropriately sized syringe, i.e. by choosing a syringe with a different sized diameter, or changing the size/force of the spring unit.


In some embodiments, one spring can be used. In some embodiments, two or more springs can be used. Some embodiments of the device can be adapted so as to receive and support any number of interchangeable springs a range of tensions.


References in this disclosure to pressure “fall-off” or “diminishing” refer to the pressure difference between ambient atmospheric pressure and the reduced pressure pertaining in the dressing at the wound site. Therefore a reference to the pressure “diminishing” or “falling off” or other similar terms is meant to refer to the circumstance where the vacuum in the dressing is actually decaying and the pressure is rising towards that of ambient atmospheric pressure.


In a modification of the device, the syringe device and spring piston withdrawal unit can be arranged to be disconnectable from the system and replaceable by a hand-held pump to quickly reduce the pressure to a desired level. The connection between the pump/syringe motive source can be a one-way valve such as a non-return check valve, for example. Thus, the syringe unit can be removed, the hand pump attached, the system quickly pumped down, the hand pump removed and the syringe unit re-attached so as to maintain the desired reduced pressure. In some embodiments, a hand pump can be a bellows type hand pump, a suction bulb type pump, or any other suitable pump, and can have some or all of the characteristics of the embodiments of any of the pumps described herein.


In some embodiments, the hand pump and the syringe system can be supported by the apparatus and arranged in parallel such that the hand pump and the syringe system can be operated individually or simultaneously. In this arrangement, for example, the hand pump can be used to provide an initial drawdown of pressure in the dressing. Additionally, during operation, the pressure provided by the syringe can be augmented by operating the hand pump.


Additionally, in some embodiments, multiple syringe and piston units can be supported by the apparatus and arranged in parallel (either with or without the hand pump described herein) so that each of the multiple syringe and piston units can individually or simultaneously provide reduced pressure to the dressing. For example, in some embodiments, the apparatus or system can be configured such that two or more syringe and piston devices are arranged in parallel such that all of the piston and syringe devices can be in fluid communication with the dressing, depending on the valve arrangement or settings. In this configuration, each of the syringe and piston devices can be individually attached to one or more springs so that, as one syringe and piston device becomes filled with exudate or has otherwise reached its capacity, another of the syringe and piston devices can be activated, so as to continue to provide reduced pressure to the wound dressing. If increased pressure drawdown to the dressing is desired, more than one of the syringe devices can be spring activated.


Additionally, the apparatus can have a valve or valve system that permits any configuration or combination of the syringe devices or the hand pump device to be placed in fluid communication with the dressing. For example, in some embodiments having just a hand pump and a single syringe device, the valve can be configured to allow either the hand pump or the syringe device to individually be in fluid communication with the dressing, or to allow both the hand pump and the syringe device to be simultaneously in fluid communication with the dressing.


In particular, FIG. 1A is a schematic representation of the side of an embodiment of a topical negative pressure therapy system 10. FIG. 1B is a schematic representation of the end of an embodiment of a spring unit 26 that can be used with the embodiments of the topical negative pressure therapy system 10 illustrated in FIG. 1A.


The system 10 can comprise a device 12 for generating a reduced pressure operably connected to a dressing 14 via a conduit 16. The dressing can have any of the features or components of any of the dressings disclosed herein, or of any of the dressings known in the art or suitable for the application of reduced pressure. As illustrated, the dressing 14 is applied to a wound site 18. The device 12 can include a syringe 20 having a slidable piston/piston rod 22 moving in a stationary cylinder 24, the piston/piston rod 22 being connected to the constant tension spring units 26 each having a coiled ribbon spring 28.


In the illustrated embodiment, a spring unit 26 can comprise two or more individual constant tension spring units 26, two being shown. As the piston 22 is withdrawn from the cylinder 24 by the spring units 26, a volume 30 in the syringe 20 is increased. A tubular spigot 32 on the end of the cylinder 24 can be connected to a four-way union 34 via a vacuum check valve 36 which can allow fluid flow in only the left to right direction as viewed in FIG. 1A. A second port of the 4-way union 34 can be connected to a waste fluid reservoir 40 configured to receive waste exudate from the wound site 18 via the flexible plastics material conduit 16 operably connected at one end to the dressing 14 and at the other end to a third port in the 4-way union 34. A vacuum pressure gauge 42 can be connected to the fourth port of the 4-way union. The spring unit 26, syringe cylinder 24 and waste reservoir 40 can all be firmly held by a base plate 44 such that they are held substantially immobile relative to each other. The end of the piston/piston rod 22 can be connected to the ends of the ribbon springs 28 by a quick connect/disconnect clip 46.


In use, the spring unit 26 can be initially disconnected from the piston/piston rod 22 and the piston 22 traversed several times in the cylinder 24 so as to quickly reduce the pressure in the dressing 14, wound site 18, and/or the waste reservoir 40 to a desired level which can be confirmed by the gauge 42. In order to perform this initial evacuation of the dressing 14 and wound site 18, a manually or automatically openable and closable exhaust valve 33 can be positioned between the syringe tubular spigot 32 and one-way valve 36 so that the syringe 20 does not need to be disconnected to expel air at every stroke. Such a valve 33 can be a non-return valve configured to vent fluid to the atmosphere on a forward stroke to minimize volume in the cylinder 24. The piston/piston rod 22 can then be reconnected to the spring unit 26 by the clip 46, while the ribbon springs 28 are withdrawn from the spring unit 26 and the piston 22 is at the extreme left-hand end of its travel, i.e. the syringe 20 is emptied. A constant spring force can then be automatically applied to the piston/piston rod 22 by the spring unit 26 to withdraw it slowly in the rightwards direction. As exudate fluid is removed from the wound and/or leakage of air occurs into the system, the piston 22 can move slowly rightwards (when oriented as in FIG. 1A), maintaining the reduced pressure in the system. The reduced constant pressure is a function of the spring force and the area of the piston/cylinder of the syringe unit 20. As fluid is drawn from the wound site 18 through the conduit 16, the fluid can reach the 4-way union and can be drawn into the waste reservoir 40. As mentioned above, multiple syringe systems devices 12 and multiple spring systems 26 can be supported by the apparatus and used in fluid communication with the dressing 14.



FIG. 2 is a schematic representation of the side of another embodiment of a topical negative pressure therapy system. The system illustrated in FIG. 2 is a modified version of the system shown in FIG. 1 and is intended for quickly creating a reduced pressure at the wound/dressing 18, 14. In this embodiment, a hand operated pump 50 is provided, some embodiments of which can have an integral pressure gauge 52. Although a hand operated pump is illustrated in FIG. 2, other pumps can be used as well, such as portable pumps including bulb pumps and portable battery powered pumps.


The pump 50 can be initially connected to a non-return one-way flow check valve 54 by means of a tapered threaded adapter 56 being a part of a connecting flexible conduit 58 between the pump 50 and check valve 54. The pump 50 can be configured to quickly reduce the pressure at the wound/dressing 18, 14 to a desired level. Once the desired pressure level is achieved, the pump 50 and conduit 58 can be disconnected from the valve 54, which can prevent or inhibit ingress of air into the dressing due to the valve 54 being a one-way valve. A pumping unit based upon the syringe 20 and constant tension spring unit 26 construction depicted in FIG. 1 can then be connected to the check valve 54 so that the desired pressure level can be automatically maintained. The pumping unit can also comprise a support to hold the cylinder 24 and spring unit 26 in fixed relationship and furthermore can be connected to the check valve 54 by a similar flexible conduit (not shown) to the flexible conduit 58 of the hand pump 50.


In some embodiments, the waste reservoir 40 can be similar or different as compared to the waste reservoir 40 described above and illustrated in FIG. 1 in that the waste reservoir 40 illustrated in FIG. 2 can have an inlet port 60 connected to the conduit 16 to allow waste exudate from the wound to be captured in the waste reservoir 40 and an outlet port 62 connected to either the hand pump 50 and/or to the aspirating syringe 20, depending on what configuration is used. The outlet port 62 can be provided with a suitable filter (not shown) such as a pathogen filter of suitable pore size to prevent liquid exudate from passing out of the port 62 and also to prevent potentially bio-hazardous bacteria from eventually passing into the atmosphere.


In a further modification of the system of FIG. 2, an electronic pressure gauge 70 can be provided, which can have its own battery power supply. Some embodiments of the apparatus shown in FIG. 2 can also be optionally fitted with an audible alarm to warn the user if the pressure has deteriorated too far from a set point and the spring needs re-energizing.


A problem with conventional types of dressing is that they generally adhere to the patient's skin in order to form a seal therewith so as to form a sealed site to which topical negative pressure therapy can be applied. Generally, such dressings may need changing every day and in some cases much more frequently. In order to inspect a wound site for progress in healing, conventional dressings generally need to be removed and then a fresh dressing applied. Due to the adhesive nature of the dressing drapes commonly used, this can cause additional trauma to the patient by frequent removal of the dressing for whatever reason. Embodiments of the present disclosure are intended to mitigate some of the disadvantages of known systems of reduced pressure dressings.


In some embodiments, the dressing can comprise materials, aspects, and configurations of other topical negative pressure dressings known in the art, arranged or modified as described herein. Some embodiments of the dressings disclosed herein can comprise a thin, flexible sheet or membrane (also referred to herein as an overlay portion) to cover the wound, as is described in greater detail below. Some arrangements of the dressing can have an aspiration conduit sealingly supported by the flexible sheet or membrane.


Some arrangements of the dressing can comprise at least two parts: a first adherent base portion to sealably surround a wound site, for example, and a second detachable portion sealably connectable and reconnectable to said first portion to seal site. The second detachable portion can be configured to completely cover and, hence, provide a seal when joined with the base portion. Alternatively, the detachable portion can be configured to have an aperture formed therein so as to not provide a complete seal when joined with the base portion. In this arrangement, as will be described in greater detail below, a thin, flexible sheet can be provided that is positioned and sealingly sandwiched between the base portion and the second detachable portion. A benefit of the separate flexible sheet is that the sheet can be changed at regular intervals or as necessary so that any bacteria that has contaminated the flexible sheet can be discarded with the sheet and, hence, removed from the vicinity of the wound without requiring other components of the dressing to be discarded.


Thus, in some arrangements, the base portion can be formed being a generally ring-like shape having a circular or non-circular perimeter or shape. For example, without limitation, the base portion can have a square, rectangular, circular, ovular, polygonal, or any other suitable shape. Additionally, the lower surface of the base portion can be planar or non-planner, depending on the contour or surface shape of the skin or other surface against which the base portion would be adhered or sealed. Because the base portion in some embodiments is configured to surround the wound, the base portion can be configured to define an aperture therethrough that is sufficiently large so that the base portion only contacts the healthy skin surrounding a wound.


As mentioned, some embodiments of the second detachable part can have a general shape that is similar to the shape of the base portion so that the tube can be joined together without any mismatch therebetween. However, because the base portion and the detachable portion are configured to be sealingly joined, the geometry of the base portion and the detachable portion pertaining to the sealing components can be different. For example, in some embodiments, the base portion can define an annular protrusion or tongue, as it is commonly referred, while the detachable portion can define an annular channel or groove configured to provide a seal when joined with the annular protrusion or tongue of the base portion. In this and other configurations, therefore, the second or detachable portion of the dressing can be detached from the first or base portion of the dressing so that the raised portion of the dressing can remain in place, adhered to the patient's skin. Additionally, the detachable portion and/or flexible sheet described above can be replaceable so that, if either of these components are contaminated such as by bacteria, they can be replaced with new, fresh components or can be cleaned or otherwise decontaminated without disturbing the wound and also without incurring the cost and time required to replace the base portion, and without causing irritation to the patient's healthy skin.


Thus, it will be seen that the first on base portion can be configured to remain in place around the wound, and tests have shown that it is feasible for the first part of the dressing to remain in place for up to a week. Additionally, in the same arrangements, the second or detachable portion can be removed by a clinician for inspection of the wound, changing or replacing of the gauze, foam, or other wound packing means within the dressing, cleansing of the wound, cleansing of the removable portions of the dressing, or for any other suitable purpose. The detachable portion can then be re-joined with the base portion without disturbing the seal between the base portion and the skin surrounding the wound. The detachable second portion need not have any adhesive on it which contacts the wound area per se.


As mentioned, the wound cavity can be provided with any suitable wound filling material known in the art. In some applications, the wound filling material can be configured to maintain the edges of the wound cavity apart from one another and to promote the growth of new material from the wound bed so as to prevent the formation of closed cavities. The embodiments of the dressing disclosed herein facilitate the use of wound filler materials by allowing any internal wound fillers, wound packing materials, or waste absorbing materials to be easily accessed by removing the second detachable portion of the dressing without disturbing the seal between the lower base portion and the patient's skin.


In arrangements where the dressing comprises a flexible sheet sandwiched between the base and the detachable portion of the dressing, the flexible sheet can provide the advantage of being able to collapse over and cover a wound filler that can be placed within the dressing. In some embodiments, the flexible sheet can be configured to cover a wound filler that protrudes above the edge of the detachable portion of the dressing in a manner that may not be achievable with a more rigid wound dressing.


In some of the embodiments described herein, because the volume or capacity of the exudate waste collecting receptacle can be limited or relatively small, the gauze or wound packing material can be selected so that the apparatuses described above can have additional means for collecting waste fluid. Providing additional means for collecting waste fluid can extend the time periods between which the waste receptacle needs to be emptied or replaced. This may be particularly useful in applications where the topical negative pressure therapy system is used as a portable system to allow patients to lead a relatively normal life while continuing their therapy (though in theory the waste receptacle could be as large as desired).


Thus, in some embodiments, the wound packing material may comprise a so-called “superabsorber” material to absorb excess waste fluids which would otherwise be aspirated to the waste receptacle. In some embodiments, between approximately 50% and approximately 100% of the fluids exuded by the wound can be absorbed by the superabsorber with the remaining portion of the fluids exuded by the wound can be aspirated to the waste receptacle or otherwise. A suitable material for a superabsorber can be polyacrylate (in particle form or otherwise), calcium alginate, and/or carboxymethycellulose.


In some embodiments, the superabsorber can be held within a porous or permeable bag within the dressing, and can be positioned adjacent the wound. In some embodiments, the wound packing material can be a composite containing the superabsorber material, such as gauze with superabsorber particles or fibers contained therein, or a foam material such as ALLEVYN PLUS™ having polyacrylate superabsorber particles therein. In some embodiments, the superabsorber material can be positioned or layered on top of a porous foam material or other suitable material so that exudate travels through the foam or other material before being absorbed by the superabsorber material. This arrangement would allow a user or medical practitioner to easily and quickly change the superabsorber material with or without changing the other wound packing materials.


Consequently, it will be seen that some embodiments of the dressing system disclosed herein can have at least two advantages. First, some embodiments of this dressing can result in reduced trauma to the patient since the base part can remain in sealing contact on the patient for much longer than with conventional topical negative pressure dressings. Additionally, the base portion can be configured so as to reduce the area of contact with the patient's skin. Furthermore, the second detachable portion need have no adhesive which contacts either sound skin or the wound itself, again leading to reduced trauma for the patient.


In the case where the wound site comprises a skin graft or skin replacement product, for example, which often are secured with minimal suture material, topical negative pressure can be used to apply a moderate pressure via a positive pressure from the ambient atmosphere to the graft to stabilise the graft and assist with complete contact over the graft area. The use of topical negative pressure in skin graft surgery also helps to prevent the graft from being continuously wet by removing any excess fluids via the aspiration conduit. The fact that the second portion may have no adhesive thereon, in contrast to conventional self-adhesive drape materials, can reduce the danger of possibly harming a delicate bond of the graft to the wound site.


The first base portion of the dressing may be provided with a conventional type of multi-layer construction to both protect adhesive coated surfaces with a removable and discardable protector layer and a support layer to assist handling of the dressing portion immediately prior to adhering to a patient. If provided with an adhesive layer, the second portion can also be provided with similar protective and support layers.


In some embodiments, however, the second or removable portion can be provided with an adhesive layer to adhere the first and second portions of the dressing together. There can be particular applications where this arrangement is preferred. Other arrangements of the dressing, as described herein, can be configured such that the base portion and the detachable portion are provided with mutually co-operating joining and sealing means.


Mutually co-operating sealing means may, in some embodiments of the present disclosure, comprise co-operating ring portions on the two parts which have engaging male and female portions (in cross section) formed from a soft, conformable material such as but not limited to a silicone rubber type material, polyurethane, PE, PP, PVC, EVA, for example. Suitable materials can have a Shore A hardness in the range from about 70 to about 100, but this range is not limiting.


Therefore, in some arrangements of the dressing, the second portion can be configured so that it forms a seal enclosure over the first base portion. For example, a second portion can be configured such that a flexible drain or window portion (whether translucent, transparent, or otherwise) can be integral or otherwise adhered to the second portion. Alternatively, some arrangements of the dressing can be configured such that a separate drape or flexible film material (such as can be formed from, without limitation, a translucent, transparent, opaque plastic material or any other suitable material) but which can be held in place by being sandwiched between the male and female co-operating portions of the base and detachable portions. Although co-operating male and female formations or features are described above for joining the base portion and the second detachable portion, alternative joining means such as magnetic material filled tapes, for example, can be used.


In particular, with reference to the accompanying figures, FIG. 3A is an exploded sectional view through the center of an embodiment of a dressing that can be used in a topical negative pressure therapy system, and FIG. 3B is a sectional view through the center of the embodiment of the dressing shown in FIG. 3A, showing a portion of the embodiment of the dressing in an assembled state.


The embodiment of the dressing 80 illustrated in FIGS. 3A and 3B can be used in the system illustrated in FIGS. 1A, 1B, and/or 2. As mentioned, FIG. 3A shows the dressing 80 in exploded form showing the constituent parts situated above a schematic wound 82 surrounded by healthy skin 84, and FIG. 3B shows a detail of the first base portion 88, the second detachable portion 90, and the occlusive drape material or membrane 92 all joined together with the membrane 92 sandwiched between the first base portion 88 and the second detachable portion 90. The dressing can comprise a first base portion 88 and a second detachable portion 90. In this embodiment, the second detachable portion 90 can be in the form of a ring member which can be removably attached to the base portion 88 by co-operating male and female engagement features described below. In some embodiments, the membrane 92 can be a separate component formed from a thin, flexible material and can be provided between the first base portion 88 and second detachable portion 90. In some embodiments, as described above, the detachable portion 90 can be configured to completely cover the base portion 88 and hence, the wound 82. In some embodiments, the membrane 92 can be integrally formed with the detachable portion 90, or can be separately formed and adhered or otherwise fixed to the detachable portion.


In some embodiments, the detachable portion 90 can be hingedly connected or otherwise tethered to the base portion 88. In some embodiments, the detachable portion 90 can be untethered from the base portion 88, so that the detachable portion 90 can be completely removed from the base portion 88.


Prior to attachment to the skin 84, the first base portion 88 can comprise a flexible plastic material backing layer 94 having a layer of pressure sensitive adhesive 96 coated on the surface 98 which is configured to contact the skin in use. The adhesive layer 96 can be initially protected by a plastic material protective layer 100 which can be peeled away prior to adhering to the patient. Depending upon the size and physical stiffness of the carrier layer 94, a further removable adhesive stiffening carrier layer (shown as dashed lines 104 in FIG. 3) can optionally be provided upon the upper surface 102 of the backing layer 94 to aid handling of the first base portion 88 after removal of the adhesive protection layer 100. The carrier layer 104 can be peeled away after attachment of the first base portion 88 to the patient. The first base portion 88 can also be provided with a connector ring 106 adhered thereto. The first base portion 88 and any other suitable component of the dressing 80 can be formed from a soft conformable material such as, but not limited to, a plastic or rubber material such as a silicone rubber or other materials as described hereinabove. The connector ring 106 can have a foot portion 108 for greater bonding strength and stability and an upstanding male engaging portion 110 molded therewith.


The second detachable portion 90 can be a ring member of corresponding size to that of connector ring member 106 and can be provided with a female engaging portion 112 to cooperate with and receive the male portion 110 of the connecting ring 106 therein. In some embodiments, the interconnection of the male and female engaging portions 110, 112 can create an airtight or approximately airtight seal. The second ring member 90 and any other suitable component of the dressing 80 can be molded from a soft conformable plastic material such that forces to join the first base portion 88 and the second detachable portion 90 are relatively low, so as to avoid trauma to the patient. Any components of the dressing 80 can be sized and shaped, so as to accommodate a wide range of wound sizes and body surface contours.


Some embodiments of the dressing can comprise an aspirant conduit configured to allow a source of reduced pressure to be applied to the volume beneath the dressing. In some embodiments, the aspirant conduit can be incorporated into the dressing by providing separate, occlusive drape portions having one or more aspirant tubes sealed thereto ready for installation in a dressing. The drape portion can be configured to be removably sandwiched between the base portion and the detachable portion, or can be configured to be integrally formed with or otherwise fixed to the second detachable portion of the dressing. This can be advantageous where a separate occlusive drape portion can be employed having no adhesive coating layer.


Some embodiments of the aspirant coolant can comprise a valve or connector configured to receive and mate with a length of tubing from, for example, the source or reduced pressure. The aspirant conduit means can be formed as an integral part of the first base dressing portion during manufacture having a flexible, overlong conduit which can be cut to a desired length, both internally and externally of the dressing site, during application of the dressing to the wound site.


Alternatively, in some embodiments, the base first portion can have a tubular spigot molded or otherwise incorporated therewith and to which an aspirant conduit can be connected. Such a spigot can have a portion of the aspirant conduit connected internally of the dressing and can have an additional portion of aspirant tube to connect to aspirating pump means after placement of the dressing on a patient.


With reference to FIGS. 3A and 3B, an aspirant conduit 120 can be incorporated in several ways into the dressing 80. In addition to the ways described above, as shown in FIG. 3A, a conduit 120 can be passed through the drape 92 and sealed thereto at points of contact 122. This can be achieved by providing occlusive drape portions having aspirant tubes sealed thereto and configured to be ready for installation in a dressing as described. Additionally, the base portion 88 can have an aperture formed therein, the aperture being configured to receive and allow a conduit to pass therethrough. The aperture can be configured so that, as the conduit is passed therethrough, a sufficient seal can be formed between the aperture and the conduit. In some embodiments, an adhesive or suitable sealing material can be applied to seal the outside surface of the conduit with the aperture.


Generally, conduits or tubes passing into the wound site in any of the embodiments described herein can be sealed to a flexible wound covering membrane or film by “pinching” the flexible covering around the conduit or tube so as to both stick the membrane material to the conduit or tube and also to itself to form a seal with the tube. Generally, the types of flexible membrane material used for wound coverings are provided with an adhesive layer such as a pressure sensitive adhesive, for example, in order for the material to adhere to the skin surrounding a wound.


In some embodiments, a conduit insertion device having a trocar supported therein can be used to pass the conduit through either the flexible sheet or the second detachable portion after the dressing has been positioned over the wound. Some arrangements of the conduit insertion device can be configured such that, after the conduit has been passed through the flexible sheet or the second detachable portion (if the flexible sheet is not use), a tabbed or flanged surface that can be formed on a portion of the conduit can be sealably adhered or otherwise attached to the outside surface of the flexible sheet or second detachable portion to secure the conduit thereto.


For example, in some embodiments, a trocar can be supported within the tubular length of conduit that can be inserted though the dressing such that the trocar protrudes past the distal end of the conduit (i.e., the end of the conduit to be positioned within the dressing). In this configuration, the trocar can be used to create a puncture hole in the flexible sheet, the second detachable portion of the dressing, and/or the base portion of the dressing to permit the tubing to pass therethrough. After the tubing has been passed therethrough, the conduit member may be advanced to a distance that is sufficient to permit an annular tabbed or flanged surface sealingly surrounding the tubing to be attached to, adhered to, or otherwise joined with the outside surface of the dressing so that an approximately hermetic seal is formed between the conduit member and the dressing. At that point, the trocar may be withdrawn and the proximal end of the tubing (i.e., the end of the tubing that is located outside of the dressing), may be connected directly or indirectly to the supply of reduced pressure.


Throughout the description and claims of this specification, the words “have,” “comprise,” “contain,” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.


Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.


Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.


While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the device or process illustrated can be made without departing from the spirit of the disclosure. Additionally, the various features and processes described above can be used independently of one another, or can be combined in various ways. All possible combinations and subcombinations are intended to fall within the scope of this disclosure.


As will be recognized, certain embodiments described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of the inventions is indicated by what is claimed in this and/or future applications rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims in this and/or future applications are to be embraced within their scope.

Claims
  • 1. A negative pressure therapy system, comprising: a suction device comprising a suction chamber including a slidable piston therein, wherein the slidable piston is configured to generate a negative pressure in the suction chamber;a dressing configured to be positioned at a wound site and to communicate the negative pressure from the suction chamber to the wound site;a first pressure sensor configured to be in communication with the dressing at the wound site and to detect a first pressure at the dressing at the wound site; anda second pressure sensor configured to be in communication with the suction chamber and to detect a second pressure in the suction chamber.
  • 2. The negative pressure therapy system of claim 1, further comprising an alarm configured to generate an alert when the negative pressure is reduced below a set point.
  • 3. The negative pressure therapy system of claim 2, wherein the alarm comprises an audible alarm.
  • 4. The negative pressure therapy system of claim 1, further comprising a spring unit, wherein the slidable piston is configured to be withdrawn from the suction chamber by the spring unit thereby increasing a volume in the suction chamber.
  • 5. The negative pressure therapy system of claim 1, further comprising a waste reservoir in fluid communication with the wound dressing and configured to collect waste exudate from the wound site.
  • 6. The negative pressure therapy system of claim 5, further comprising a filter configured to prevent liquid exudate from passing out of the waste reservoir.
PRIORITY INFORMATION

This application is a continuation of U.S. application Ser. No. 16/201,508, filed Nov. 27, 2018, which is a continuation of U.S. application Ser. No. 15/366,999, filed Dec. 1, 2016 and now U.S. Pat. No. 10,143,784, which is a continuation of U.S. application Ser. No. 14/447,423, filed Jul. 30, 2014, which is a continuation of U.S. application Ser. No. 12/744,302, filed May 21, 2010 and now U.S. Pat. No. 8,808,259, which is a U.S. National Phase of International Application No. PCT/US2008/084433, filed Nov. 21, 2008, designating the U.S. and published on May 28, 2009 as WO 2009/067711, which claims priority benefit under 35 U.S.C. § 119(e) of Provisional Application 60/989,723 filed Nov. 21, 2007 and titled SUCTION DEVICE AND DRESSING, the disclosure of each which are hereby incorporated by reference in its entirety.

US Referenced Citations (514)
Number Name Date Kind
2318888 Sanders May 1943 A
2682873 Idnis et al. Jul 1954 A
3115138 Mcelvenny et al. Dec 1963 A
3286711 Macleod Nov 1966 A
3315665 Macleod Apr 1967 A
3520300 Flower, Jr. Jul 1970 A
3568675 Harvey Mar 1971 A
3841331 Wilder et al. Oct 1974 A
3896810 Akiyama Jul 1975 A
3972328 Chen Aug 1976 A
4029598 Neisius et al. Jun 1977 A
4112949 Rosenthal et al. Sep 1978 A
4117551 Brooks et al. Sep 1978 A
4136696 Nehring Jan 1979 A
4316466 Babb Feb 1982 A
4382441 Svedman May 1983 A
4404924 Goldberg et al. Sep 1983 A
4468227 Jensen Aug 1984 A
4480638 Schmid Nov 1984 A
4525166 Leclerc Jun 1985 A
4529402 Weilbacher et al. Jul 1985 A
4538920 Drake Sep 1985 A
4540412 Van Overloop Sep 1985 A
4648870 Goldberg et al. Mar 1987 A
4710165 McNeil Dec 1987 A
4713052 Beck et al. Dec 1987 A
4728499 Fehder Mar 1988 A
4743232 Kruger May 1988 A
4753536 Spehar et al. Jun 1988 A
4767026 Keller et al. Aug 1988 A
4771919 Ernst Sep 1988 A
4778446 Jensen Oct 1988 A
4787888 Fox Nov 1988 A
4795428 Hwang Jan 1989 A
4795435 Steer Jan 1989 A
4798583 Beck et al. Jan 1989 A
4813942 Alvarez Mar 1989 A
4872450 Austad Oct 1989 A
4930997 Bennett Jun 1990 A
4953565 Tachibana Sep 1990 A
4969880 Zamierowski Nov 1990 A
4979944 Luzsicza Dec 1990 A
4981474 Bopp et al. Jan 1991 A
5010115 Grisoni Apr 1991 A
5011381 Neward Apr 1991 A
5056510 Gilman Oct 1991 A
5064653 Sessions et al. Nov 1991 A
5071409 Rosenberg Dec 1991 A
5080493 McKown et al. Jan 1992 A
5152757 Eriksson Oct 1992 A
5167613 Karami Dec 1992 A
5176663 Svedman Jan 1993 A
5181905 Flam Jan 1993 A
5238732 Krishnan Aug 1993 A
5249709 Duckworth et al. Oct 1993 A
5266326 Barry et al. Nov 1993 A
5278100 Doan Jan 1994 A
5279550 Habib Jan 1994 A
5298015 Komatsuzaki Mar 1994 A
5333760 Simmen Aug 1994 A
5342376 Ruff Aug 1994 A
5344415 DeBusk Sep 1994 A
5358494 Svedman Oct 1994 A
5437622 Carion Aug 1995 A
5437651 Todd Aug 1995 A
5445604 Lang Aug 1995 A
5456745 Roreger et al. Oct 1995 A
5505210 Clement Apr 1996 A
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5556375 Ewall Sep 1996 A
5562615 Nassif Oct 1996 A
5582596 Fukunaga et al. Dec 1996 A
5583114 Barrows et al. Dec 1996 A
5607388 Ewall Mar 1997 A
5609271 Keller et al. Mar 1997 A
5612050 Rowe et al. Mar 1997 A
5636643 Argenta Jun 1997 A
5645081 Argenta Jul 1997 A
5660823 Chakrabarti et al. Aug 1997 A
5662924 Rhodes Sep 1997 A
5697920 Gibbons Dec 1997 A
5707499 Joshi et al. Jan 1998 A
5713881 Rezai et al. Feb 1998 A
5717030 Dunn et al. Feb 1998 A
5747064 Burnett et al. May 1998 A
5759570 Arnold Jun 1998 A
5776193 Kwan et al. Jul 1998 A
5795584 Totakura et al. Aug 1998 A
5834007 Kubota Nov 1998 A
5852126 Barnard et al. Dec 1998 A
5874500 Rhee et al. Feb 1999 A
5928265 Fleischmann Jul 1999 A
5945115 Dunn et al. Aug 1999 A
5954680 Augustine Sep 1999 A
5962010 Greff et al. Oct 1999 A
5998472 Berger et al. Dec 1999 A
6010527 Augustine et al. Jan 2000 A
6048337 Svedman Apr 2000 A
6071267 Zamierowski Jun 2000 A
6110197 Augustine et al. Aug 2000 A
6135116 Vogel Oct 2000 A
6142982 Hunt et al. Nov 2000 A
6143352 Clark et al. Nov 2000 A
6165201 Sawhney et al. Dec 2000 A
6168788 Wortham Jan 2001 B1
6174306 Fleischmann Jan 2001 B1
6214332 Askill et al. Apr 2001 B1
6241747 Ruff Jun 2001 B1
6252129 Coffee Jun 2001 B1
6254567 Treu et al. Jul 2001 B1
6287316 Agarwal Sep 2001 B1
6345623 Heaton Feb 2002 B1
6391294 Dettmar et al. May 2002 B1
6398761 Bills et al. Jun 2002 B1
6447802 Sessions et al. Sep 2002 B2
6458109 Henley et al. Oct 2002 B1
6486285 Fujita Nov 2002 B2
6488643 Tumey Dec 2002 B1
6493568 Bell Dec 2002 B1
6495127 Wallace et al. Dec 2002 B1
6509031 Miller et al. Jan 2003 B1
6521251 Askill et al. Feb 2003 B2
6547467 Quintero Apr 2003 B2
6548730 Patel et al. Apr 2003 B1
6575940 Levinson et al. Jun 2003 B1
6596704 Court et al. Jul 2003 B1
6626891 Ohmstede Sep 2003 B2
6627216 Brandt et al. Sep 2003 B2
6629774 Gruendeman Oct 2003 B1
6685681 Lockwood et al. Feb 2004 B2
6730299 Tayot et al. May 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6764462 Risk, Jr. Jul 2004 B2
6790438 Constancis et al. Sep 2004 B1
6824533 Risk, Jr. Nov 2004 B2
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7004915 Boynton et al. Feb 2006 B2
7070584 Johnson et al. Jul 2006 B2
7108683 Zamierowski Sep 2006 B2
7118545 Boyde Oct 2006 B2
7128735 Weston Oct 2006 B2
7129210 Lowinger et al. Oct 2006 B2
7141714 Nielsen Nov 2006 B2
7214202 Vogel et al. May 2007 B1
7216651 Argenta et al. May 2007 B2
7279612 Heaton et al. Oct 2007 B1
7303757 Schankereli et al. Dec 2007 B2
7361184 Joshi Apr 2008 B2
7381859 Hunt et al. Jun 2008 B2
7494482 Orgill et al. Feb 2009 B2
7524315 Blott et al. Apr 2009 B2
7534927 Lockwood et al. May 2009 B2
7553306 Hunt et al. Jun 2009 B1
7569742 Haggstrom et al. Aug 2009 B2
7605298 Bechert et al. Oct 2009 B2
7608066 Vogel Oct 2009 B2
7611500 Lina et al. Nov 2009 B1
7615036 Joshi et al. Nov 2009 B2
7622629 Aali Nov 2009 B2
7625362 Boehringer Dec 2009 B2
7645269 Zamierowski Jan 2010 B2
7651484 Heaton Jan 2010 B2
7699823 Haggstrom Apr 2010 B2
7699830 Martin Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7717313 Criscuolo et al. May 2010 B2
7718249 Russell et al. May 2010 B2
7722582 Lina et al. May 2010 B2
7745681 Ferguson Jun 2010 B1
7749531 Booher Jul 2010 B2
7753894 Blott et al. Jul 2010 B2
7754937 Boehringer et al. Jul 2010 B2
7758554 Lina et al. Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759538 Fleischmann Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7763769 Johnson et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7776028 Miller et al. Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7790945 Watson, Jr. Sep 2010 B1
7790946 Mulligan Sep 2010 B2
7794450 Blott et al. Sep 2010 B2
7803980 Griffiths et al. Sep 2010 B2
7811269 Boynton et al. Oct 2010 B2
7815616 Boehringer et al. Oct 2010 B2
7828782 Suzuki Nov 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7846141 Weston Dec 2010 B2
7862831 Wang et al. Jan 2011 B2
7880050 Robinson et al. Feb 2011 B2
7883494 Martin Feb 2011 B2
7896823 Mangrum et al. Mar 2011 B2
7909805 Weston Mar 2011 B2
7910135 St. John et al. Mar 2011 B2
7910791 Coffey Mar 2011 B2
7922703 Riesinger Apr 2011 B2
7927319 Lawhorn Apr 2011 B2
7959624 Riesinger Jun 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
8007164 Miyano et al. Aug 2011 B2
8007257 Heaton et al. Aug 2011 B2
8007481 Schuessler et al. Aug 2011 B2
8034037 Adams et al. Oct 2011 B2
8062272 Weston Nov 2011 B2
8062273 Weston Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8097272 Addison Jan 2012 B2
8105295 Blott et al. Jan 2012 B2
8118794 Weston Feb 2012 B2
8119160 Looney et al. Feb 2012 B2
8133211 Cavanaugh, II et al. Mar 2012 B2
8152785 Vitaris Apr 2012 B2
8158844 McNeil Apr 2012 B2
8162907 Heagle Apr 2012 B2
8162909 Blott et al. Apr 2012 B2
8172818 Locke May 2012 B2
8192409 Hardman et al. Jun 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8216198 Heagle Jul 2012 B2
8226942 Charier et al. Jul 2012 B2
8235955 Blott et al. Aug 2012 B2
8235972 Adahan Aug 2012 B2
8241261 Randolph et al. Aug 2012 B2
8246606 Stevenson et al. Aug 2012 B2
8251979 Malhi Aug 2012 B2
8257327 Blott Sep 2012 B2
8273368 Ambrosio et al. Sep 2012 B2
8282611 Weston Oct 2012 B2
8303552 Weston Nov 2012 B2
8308703 Heaton Nov 2012 B2
8308714 Weston Nov 2012 B2
8323264 Weston Dec 2012 B2
8338402 Fry et al. Dec 2012 B2
8348910 Blott et al. Jan 2013 B2
8366691 Pratt Feb 2013 B2
8366692 Weston Feb 2013 B2
8372049 Jaeb Feb 2013 B2
8372050 Jaeb Feb 2013 B2
8382731 Johannison Feb 2013 B2
8398614 Blott Mar 2013 B2
8409157 Haggstrom Apr 2013 B2
8409170 Locke Apr 2013 B2
8410189 Carnahan et al. Apr 2013 B2
8425478 Olson Apr 2013 B2
8444612 Patel May 2013 B2
8449509 Weston May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8529548 Blott Sep 2013 B2
8535296 Blott et al. Sep 2013 B2
8545464 Weston Oct 2013 B2
8545466 Andresen et al. Oct 2013 B2
8551060 Schuessler Oct 2013 B2
8628505 Weston Jan 2014 B2
8641691 Fink Feb 2014 B2
8652111 Pratt Feb 2014 B2
8663198 Buan et al. Mar 2014 B2
8679079 Heaton et al. Mar 2014 B2
8715256 Greener May 2014 B2
8753670 Delmotte Jun 2014 B2
8764732 Hartwell Jul 2014 B2
8795243 Weston Aug 2014 B2
8795635 Tamarkin et al. Aug 2014 B2
8795713 Makower et al. Aug 2014 B2
8808259 Walton Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
8834451 Blott et al. Sep 2014 B2
8834452 Hudspeth et al. Sep 2014 B2
8852170 Weston et al. Oct 2014 B2
8905985 Allen Dec 2014 B2
8915895 Jaeb Dec 2014 B2
8926592 Blott Jan 2015 B2
8945030 Weston Feb 2015 B2
8951235 Allen Feb 2015 B2
8951236 Heaton Feb 2015 B2
8956336 Haggstrom Feb 2015 B2
8968773 Thomas et al. Mar 2015 B2
9012714 Fleischmann Apr 2015 B2
9017302 Vitaris Apr 2015 B2
9028872 Gaserod et al. May 2015 B2
9044579 Blott et al. Jun 2015 B2
9050209 Coulthard Jun 2015 B2
9061095 Adie et al. Jun 2015 B2
9084845 Adie Jul 2015 B2
9138515 Locke Sep 2015 B2
9168330 Joshi et al. Oct 2015 B2
9199012 Vitaris et al. Dec 2015 B2
9220822 Hartwell Dec 2015 B2
9302033 Riesinger Apr 2016 B2
9375353 Vitaris et al. Jun 2016 B2
9375521 Hudspeth et al. Jun 2016 B2
9381283 Adams et al. Jul 2016 B2
9387126 Blott et al. Jul 2016 B2
9446178 Blott et al. Sep 2016 B2
9452245 Jaeb Sep 2016 B2
9452246 Heaton Sep 2016 B2
9452248 Blott et al. Sep 2016 B2
9456928 Haggstrom Oct 2016 B2
9629986 Patel et al. Apr 2017 B2
9669138 Joshi et al. Jun 2017 B2
9795725 Joshi et al. Oct 2017 B2
9844473 Blott et al. Dec 2017 B2
9956121 Hartwell May 2018 B2
9962474 Greener May 2018 B2
10010656 Jaeb Jul 2018 B2
10016309 Hartwell Jul 2018 B2
10105471 Weston Oct 2018 B2
10124097 Pratt Nov 2018 B2
10143784 Walton Dec 2018 B2
10307518 Heaton Jun 2019 B2
11020516 Jaeb Jun 2021 B2
11154651 Pratt Oct 2021 B2
11167073 Heaton Nov 2021 B2
20010004082 Keller et al. Jun 2001 A1
20010034499 Sessions et al. Oct 2001 A1
20010043913 Spaans et al. Nov 2001 A1
20020038826 Hurray et al. Apr 2002 A1
20020077661 Saadat Jun 2002 A1
20020115951 Norstrem Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020122771 Holland et al. Sep 2002 A1
20020143286 Tumey Oct 2002 A1
20020145007 Sawhney et al. Oct 2002 A1
20020187182 Kramer et al. Dec 2002 A1
20020198490 Wirt et al. Dec 2002 A1
20020198503 Risk, Jr. Dec 2002 A1
20020198504 Risk, Jr. Dec 2002 A1
20030014022 Lockwood Jan 2003 A1
20030040478 Drucker et al. Feb 2003 A1
20030040687 Boynton Feb 2003 A1
20030069535 Shalaby Apr 2003 A1
20030093041 Risk, Jr. May 2003 A1
20030125646 Whitlock Jul 2003 A1
20030143189 Askill et al. Jul 2003 A1
20030183653 Bills Oct 2003 A1
20040033466 Shellard et al. Feb 2004 A1
20040037897 Benjamin et al. Feb 2004 A1
20040049187 Burnett et al. Mar 2004 A1
20040057855 Gerlach et al. Mar 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040073152 Karason et al. Apr 2004 A1
20040127836 Sigurjonsson et al. Jul 2004 A1
20040167617 Voellmicke et al. Aug 2004 A1
20040171998 Marasco, Jr. Sep 2004 A1
20050058694 Nielsen Mar 2005 A1
20050070835 Joshi Mar 2005 A1
20050137539 Biggie Jun 2005 A1
20050222527 Miller et al. Oct 2005 A1
20050222528 Weston Oct 2005 A1
20050230422 Muller et al. Oct 2005 A1
20050261642 Weston Nov 2005 A1
20060009744 Erdman et al. Jan 2006 A1
20060025727 Boehringer Feb 2006 A1
20060052839 Kim et al. Mar 2006 A1
20060079599 Arthur Apr 2006 A1
20060155260 Blott et al. Jul 2006 A1
20060173514 Biel et al. Aug 2006 A1
20060253082 McIntosh et al. Nov 2006 A1
20060273109 Keller Dec 2006 A1
20070004896 Ito et al. Jan 2007 A1
20070009580 DiCosmo et al. Jan 2007 A1
20070027414 Hoffman et al. Feb 2007 A1
20070032762 Vogel Feb 2007 A1
20070032763 Vogel Feb 2007 A1
20070040454 Freudenberger et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070066946 Haggstrom Mar 2007 A1
20070129707 Blott et al. Jun 2007 A1
20070141101 Nugent et al. Jun 2007 A1
20070147947 Stenton et al. Jun 2007 A1
20070164047 Reidt et al. Jul 2007 A1
20070167926 Blott et al. Jul 2007 A1
20070185463 Mulligan Aug 2007 A1
20070203062 Ellis-Behnke et al. Aug 2007 A1
20070219512 Heaton Sep 2007 A1
20070219532 Karpowicz Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070265586 Joshi et al. Nov 2007 A1
20070276195 Xu et al. Nov 2007 A1
20070276309 Xu et al. Nov 2007 A1
20080004549 Anderson et al. Jan 2008 A1
20080031748 Ihle et al. Feb 2008 A1
20080041401 Casola Feb 2008 A1
20080060550 Macdonald et al. Mar 2008 A1
20080065001 DiNucci et al. Mar 2008 A1
20080071214 Locke Mar 2008 A1
20080071216 Locke Mar 2008 A1
20080082059 Fink Apr 2008 A1
20080089173 Lu et al. Apr 2008 A1
20080091133 Matter Apr 2008 A1
20080132821 Propp et al. Jun 2008 A1
20080139674 Archambeau et al. Jun 2008 A1
20080200857 Lawhorn Aug 2008 A1
20080206155 Tamarkin et al. Aug 2008 A1
20080208163 Wilkie Aug 2008 A1
20080234641 Locke Sep 2008 A1
20080254103 Harris et al. Oct 2008 A1
20080287880 Keller Nov 2008 A1
20080294127 Blott et al. Nov 2008 A1
20080300555 Olson et al. Dec 2008 A1
20080300578 Freedman Dec 2008 A1
20080306456 Riesinger Dec 2008 A1
20080314929 Keller Dec 2008 A1
20090012482 Pinto et al. Jan 2009 A1
20090020561 Keller Jan 2009 A1
20090022779 Kelly et al. Jan 2009 A1
20090030086 Eady et al. Jan 2009 A1
20090030402 Adahan Jan 2009 A1
20090054855 Blott et al. Feb 2009 A1
20090054856 Mormino et al. Feb 2009 A1
20090093550 Rolfes et al. Apr 2009 A1
20090098073 Macdonald et al. Apr 2009 A1
20090105671 Daggar et al. Apr 2009 A1
20090125004 Shen et al. May 2009 A1
20090134186 Keller May 2009 A1
20090157017 Ambrosio Jun 2009 A1
20090157024 Song Jun 2009 A1
20090187131 Fitzgerald Jul 2009 A1
20090196844 Choi et al. Aug 2009 A1
20090221977 Blott et al. Sep 2009 A1
20090227969 Jaeb Sep 2009 A1
20090234306 Vitaris Sep 2009 A1
20090240185 Jaeb Sep 2009 A1
20090254066 Heaton Oct 2009 A1
20090275872 Addison et al. Nov 2009 A1
20090299251 Buan Dec 2009 A1
20090299255 Kazala, Jr. et al. Dec 2009 A1
20090299306 Buan Dec 2009 A1
20090306630 Locke Dec 2009 A1
20090312723 Blott et al. Dec 2009 A1
20100022972 Lina et al. Jan 2010 A1
20100030132 Niezgoda et al. Feb 2010 A1
20100036305 Green Feb 2010 A1
20100036334 Heagle et al. Feb 2010 A1
20100042074 Weston et al. Feb 2010 A1
20100069829 Hutchinson et al. Mar 2010 A1
20100069850 Fabo Mar 2010 A1
20100069858 Olson Mar 2010 A1
20100094234 Ramella et al. Apr 2010 A1
20100106112 Vogel Apr 2010 A1
20100106117 Lockwood et al. Apr 2010 A1
20100122417 Vrzalik et al. May 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100150991 Bernstein Jun 2010 A1
20100191196 Heagle Jul 2010 A1
20100210986 Sanders et al. Aug 2010 A1
20100230467 Criscuolo et al. Sep 2010 A1
20100249733 Blott et al. Sep 2010 A9
20100262090 Riesinger Oct 2010 A1
20100262091 Larsson Oct 2010 A1
20100262094 Walton Oct 2010 A1
20100280469 Hall et al. Nov 2010 A1
20100305526 Robinson et al. Dec 2010 A1
20110021431 Jones et al. Jan 2011 A1
20110028919 Johnnison et al. Feb 2011 A1
20110033503 Sinko et al. Feb 2011 A1
20110086077 McCrea et al. Apr 2011 A1
20110118683 Weston May 2011 A1
20110130712 Topaz Jun 2011 A1
20110257572 Locke et al. Oct 2011 A1
20110282309 Adie et al. Nov 2011 A1
20120130332 Cotton et al. May 2012 A1
20120136325 Allen May 2012 A1
20120165764 Allen Jun 2012 A1
20120232502 Lowing Sep 2012 A1
20120245540 Zimnitsky et al. Sep 2012 A1
20120271256 Locke Oct 2012 A1
20130053797 Locke et al. Feb 2013 A1
20130096518 Hall et al. Apr 2013 A1
20130110058 Adie May 2013 A1
20130138054 Fleischmann May 2013 A1
20130150814 Buan Jun 2013 A1
20130172805 Truckai Jul 2013 A1
20130172839 Locke Jul 2013 A1
20130317406 Locke et al. Nov 2013 A1
20130331823 Askem Dec 2013 A1
20130338614 Heaton et al. Dec 2013 A1
20140031771 Locke et al. Jan 2014 A1
20140115893 Pratt May 2014 A1
20140163490 Locke et al. Jun 2014 A1
20140228786 Croizat et al. Aug 2014 A1
20140249495 Mumby et al. Sep 2014 A1
20140276490 Locke et al. Sep 2014 A1
20140276491 Luckemeyer et al. Sep 2014 A1
20140316359 Collinson et al. Oct 2014 A1
20140358097 Walton Dec 2014 A1
20150051560 Askem Feb 2015 A1
20150065965 Haggstrom et al. Mar 2015 A1
20150065966 Adie Mar 2015 A1
20150100045 Allen Apr 2015 A1
20150119830 Luckemeyer et al. Apr 2015 A1
20150119832 Locke Apr 2015 A1
20150141941 Allen et al. May 2015 A1
20150174304 Askem Jun 2015 A1
20150217032 Allen Aug 2015 A1
20160175156 Locke et al. Jun 2016 A1
20160317357 Vitaris et al. Nov 2016 A1
20170007753 Blott et al. Jan 2017 A1
20170128642 Buan May 2017 A1
20170143882 Walton May 2017 A1
20170181896 Hartwell Jun 2017 A1
20170181897 Hartwell Jun 2017 A1
20170252496 Blott et al. Sep 2017 A1
20180064581 Lowing Mar 2018 A1
20190091383 Weston Mar 2019 A1
20190167865 Walton Jun 2019 A1
20220355020 Walton Nov 2022 A1
Foreign Referenced Citations (128)
Number Date Country
2349638 May 2000 CA
3443101 May 1986 DE
3935818 May 1991 DE
202004017052 Jun 2005 DE
202005019670 Apr 2006 DE
0340018 Nov 1989 EP
0521434 Jan 1993 EP
0858810 Aug 1998 EP
0888141 Jan 1999 EP
1007015 Jun 2000 EP
1029585 Aug 2000 EP
1105171 Jun 2001 EP
1105180 Jun 2001 EP
1107813 Jun 2001 EP
1030657 Oct 2001 EP
1306123 May 2003 EP
1440737 Jul 2004 EP
1476217 Mar 2008 EP
1923077 May 2008 EP
1955887 Aug 2008 EP
2111804 Oct 2009 EP
2218431 Aug 2010 EP
2462908 Jun 2012 EP
1163907 Oct 1958 FR
1255395 Dec 1971 GB
2047438 Nov 1980 GB
2288734 Nov 1995 GB
2424582 Oct 2006 GB
2435419 Aug 2007 GB
WO-8300742 Mar 1983 WO
WO-9209301 Jun 1992 WO
WO-9209651 Jun 1992 WO
WO-9306802 Apr 1993 WO
WO-9309176 May 1993 WO
WO-9420133 Sep 1994 WO
WO-9605873 Feb 1996 WO
WO-9640174 Dec 1996 WO
WO-9703717 Feb 1997 WO
WO-9733922 Sep 1997 WO
WO-9742986 Nov 1997 WO
WO-9803267 Jan 1998 WO
WO-9806444 Feb 1998 WO
WO-9846178 Oct 1998 WO
WO-9917698 Apr 1999 WO
WO-9930629 Jun 1999 WO
WO-9947097 Sep 1999 WO
WO-9965536 Dec 1999 WO
WO-0038752 Jul 2000 WO
WO-0061206 Oct 2000 WO
WO-0062827 Oct 2000 WO
WO-0064396 Nov 2000 WO
WO-0162312 Aug 2001 WO
WO-0166017 Sep 2001 WO
WO-0193793 Dec 2001 WO
WO-0202079 Jan 2002 WO
WO-02070040 Sep 2002 WO
WO-02083046 Oct 2002 WO
WO-02094256 Nov 2002 WO
WO-02102864 Dec 2002 WO
WO-03030966 Apr 2003 WO
WO-03074100 Sep 2003 WO
WO-2004037334 May 2004 WO
WO-2004054632 Jul 2004 WO
WO-2004077387 Sep 2004 WO
WO-2005017000 Feb 2005 WO
WO-2005018695 Mar 2005 WO
WO-2005025447 Mar 2005 WO
WO-2005046761 May 2005 WO
WO-2005046762 May 2005 WO
WO-2005051461 Jun 2005 WO
WO-2005105174 Nov 2005 WO
WO-2005105175 Nov 2005 WO
WO-2005105176 Nov 2005 WO
WO-2005118011 Dec 2005 WO
WO-2005123170 Dec 2005 WO
WO-2006014534 Feb 2006 WO
WO-2006030054 Mar 2006 WO
WO-2006034128 Mar 2006 WO
WO-2006046060 May 2006 WO
WO-2006052839 May 2006 WO
WO-2006135506 Dec 2006 WO
WO-2007030599 Mar 2007 WO
WO-2007030601 Mar 2007 WO
WO-2007041642 Apr 2007 WO
WO-2007062024 May 2007 WO
WO-2007067685 Jun 2007 WO
WO-2007070570 Jun 2007 WO
WO-2007084792 Jul 2007 WO
WO-2007085396 Aug 2007 WO
WO-2007087809 Aug 2007 WO
WO-2007088530 Aug 2007 WO
WO-2007106594 Sep 2007 WO
WO-2007124198 Nov 2007 WO
WO-2008036345 Mar 2008 WO
WO-2008039223 Apr 2008 WO
WO-2008076407 Jun 2008 WO
WO-2008082444 Jul 2008 WO
WO-2008112304 Sep 2008 WO
WO-2008134544 Nov 2008 WO
WO-2008134774 Nov 2008 WO
WO-2008135997 Nov 2008 WO
WO-2008141228 Nov 2008 WO
WO-2008141470 Nov 2008 WO
WO-2009019227 Feb 2009 WO
WO-2009019229 Feb 2009 WO
WO-2009034322 Mar 2009 WO
WO-2009042514 Apr 2009 WO
WO-2009047524 Apr 2009 WO
WO-2009052193 Apr 2009 WO
WO-2009060327 May 2009 WO
WO-2009062327 May 2009 WO
WO-2009066105 May 2009 WO
WO-2009070905 Jun 2009 WO
WO-2009077722 Jun 2009 WO
WO-2009078790 Jun 2009 WO
WO-2009088926 Jul 2009 WO
WO-2009103031 Aug 2009 WO
WO-2009124100 Oct 2009 WO
WO-2009126833 Oct 2009 WO
WO-2009145703 Dec 2009 WO
WO-2009146441 Dec 2009 WO
WO-2009158128 Dec 2009 WO
WO-2010006182 Jan 2010 WO
WO-2010033271 Mar 2010 WO
WO-2010051068 May 2010 WO
WO-2010059712 May 2010 WO
WO-2010142959 Dec 2010 WO
WO-2010147533 Dec 2010 WO
Non-Patent Literature Citations (17)
Entry
Advantec MFS, Inc., “Membrane Filters” (catalog), retrieved from http://www.advantecmfs.com/catalog/filt/membrane.pdf, on Jan. 29, 2016, Copyright 2001-2011, 17 pages.
Bevan D., et al., “Diverse and potent activities of HGF/SF in skin wound repair,” Journal of Pathology, vol. 203, 2004, pp. 831-838.
Greer S.E., et al., “Techniques for Applying Subatmospheric Pressure Dressing to Wounds in Difficult Regions of Anatomy,” JWOCN, vol. 26(5), Sep. 1999, pp. 250-253.
Hersle K., et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies,” The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, pp. 35-37.
Info V.A.C. User Manual, KCI on Dec. 1, 2006 in 76 pages.
International Preliminary Report on Patentability for Application No. PCT/US2008/084433, dated May 25, 2010, 12 pages.
International Search Report for Application No. PCT/US2008/084433 dated Oct. 15, 2009, 5 pages.
Invitation to Pay Additional Fees and Partial Search Report for Application No. PCT/US2008/084433, dated Jul. 16, 2009, 3 pages.
Kendall ULTEC Hydrocolloid Dressing (4x4“),” Product Ordering Page, web page downloaded on Jul. 13, 2014, 1 page.
Landis E.M., et al., “The Effects of Alternate Suction and Pressure on Blood Flow to the Lower Extremities,” Alternate Suction and Pressure, J Clin Invest, Sep. 1993, vol. 12 (5), pp. 925-961.
Mitchell R.N., et al., “Role of Stem Cells in Tissue Homeostasis,” Pocket Companion to Robbins and Cotran Pathologic Basis of Disease, 7th Edition, 2006, p. 55 (3 pages).
Morykwas M.J., et al., “Nonsurgical Modalities to Enhance Healing and Care of Soft Tissue Wounds,” Journal of the Southern Orthopaedic Association, vol. 6, No. 4, 1997, pp. 279-288.
Nursing75., “Wound Suction: Better Drainage with Fewer Problems,” Oct. 1975, pp. 52-53.
Protz K., “Modern Wound Dressings Support the Healing Process,” Wound care: Indications and Application, Geriatrie Journal, Apr. 2005, pp. 3333-3339 (17 pages with English translation).
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System,” Spiral Booklet, Mar. 2011, 7 pages.
Technology Watch, May 1989, 1 page.
Westaby S., et al., “A Wound Irrigation Device,” The Lancet, Sep. 2, 1978, pp. 503-504.
Related Publications (1)
Number Date Country
20220355020 A1 Nov 2022 US
Provisional Applications (1)
Number Date Country
60989723 Nov 2007 US
Continuations (4)
Number Date Country
Parent 16201508 Nov 2018 US
Child 17752736 US
Parent 15366999 Dec 2016 US
Child 16201508 US
Parent 14447423 Jul 2014 US
Child 15366999 US
Parent 12744302 US
Child 14447423 US